Live
- IPL 2024: Fraser-McGurk, Porel fifties; Stubbs’ 41 propel DC to 221/8 against RR
- U20 men’s football nationals: Kerala beat Haryana to enter quarters; A.P. draw with Gujarat
- EPFO evaluating course of action over HC ruling on foreign workers
- Political slugfest surfaces in Bengal after SC puts interim stay on cancellation of 25,753 school jobs
- Apple launches iPad Pro with M4 chip and AI capabilities
- Congress stands for National unity says Arathi Krishna
- The dynamics of tax cuts and collections under Modi govt: A tale of prosperity
- ‘Inspiring to see the focus of sports expanding beyond cricket’: State-of-the-Art sports arena unveiled in Delhi
- Voltas Q4 net profit dips 19 per cent, declares dividend of Rs 5.50 per share
- Madigas should Vote for BJP to protect their self respect.Manda Krishna madiga
Sputnik vaccine gets nod
Serum Institute seeks test licence from DCGI to manufacture Covid vaccine Sputnik V
- 3rd vaccine to get emergency use approval in India
- Has second largest number of approvals globally
- Made in India by Dr Reddy's, it has 91.6% effectiveness
New Delhi: Russia's Covid vaccine Sputnik V has been cleared for emergency use by India's drug regulator - the Drugs Controller General of India (DCGI).
As India sees an unprecedented surge in cases, Sputnik V becomes the third coronavirus vaccine to be cleared by the drug regulator.
Two vaccines - the Serum Institute of India's Covishield and Bharat Biotech's Covaxin - were cleared in January.
In a statement, the Russian Direct Investment Fund (Russia's sovereign wealth fund) said that India has become the 60th country to approve the two-dose vaccine.
The RDIF has reached agreements with five pharmaceutical firms in the country - Gland Pharma, Hetero Biopharma, Panacea Biotec, Stelis Biopharma, Virchow Biotech - aimed at production of 850 million doses per year.
But limited doses are likely to be manufactured by April-end; production will be ramped up gradually.
"Sputnik V ranks second among coronavirus vaccines globally in terms of the number of approvals issued by government regulators," the statement read.
Manufactured in India by Dr Reddy's, it has the highest effectiveness - 91.6 per cent -- after the Moderna and Pfizer shots. Dr Reddy's had applied on February 19 for emergency use of the vaccine, which is in Phase 3 of clinical trials in India.
It was recommended for use by the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organization on Monday.
India kicked off the world's largest inoculation drive on January 16 and more than 10 crore doses have been administered so far.
However, many parts in the country are fighting a fresh Covid wave and several state governments have said they're running low on vaccine stocks.
